Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology - 1 Jul 2013

Fabbri Chiara, Drago Antonio, Serretti Alessandro

Abstract excerpt

The glutamatergic system has been suggested as a modulator of rapid antidepressant response. Thus, 44 glutamatergic genes were selected according to the literature and investigated in 1541 major depressive patients from the STAR*D genome wide dataset. Outcomes of interest were early response (2nd week) and late response (from the 4th to the 14th week) compared to non-response and stability of response through the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Depressive Disorder, Major
Share to Antidepressive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Black or African American

Share to Citalopram

Share to Databases, Genetic

Share to Glutamic Acid

Share to Receptors, Metabotropic Glutamate

Share to White People

Source

Identifiers

PMID: 22884879
DOI: 10.1016/j.euroneuro.2012.07.006

Genes

GRM7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D.PMID 22884879Read ↗

Genetic Markers for Later Remission in Response to Early Improvement of Antidepressants.Semantic proximity Read ↗

A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment.Semantic proximity Read ↗

Antidepressant treatment response is modulated by genetic and environmental factors and their interactionsSemantic proximity Read ↗

New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation.Semantic proximity Read ↗

Significant association of GRM7 and GRM8 genes with schizophrenia and major depressive disorder in the Han Chinese population.Semantic proximity Read ↗

The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes.Semantic proximity Read ↗

Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort.Semantic proximity Read ↗

Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depressionSemantic proximity Read ↗

The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis.Semantic proximity Read ↗

Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.Semantic proximity Read ↗

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.Semantic proximity Read ↗

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.